Zoster Vaccine: Current Status and Future Prospects
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Live, attenuated Oka/Merck varicella-zoster virus (VZV) vaccine (zoster vaccine) protects immunocompetent adults from herpes zoster and its complications. Success of zoster vaccine in preventing the clinical manifestations of latent VZV reactivation contrasts with the failure to achieve similar results with vaccination to prevent recurrent herpes simplex. This reflects major differences in the pathophysiology of latency and reactivation of these 2 alphaherpesviruses. The Shingles Prevention Study and many others have demonstrated that VZV-specific cell-mediated immunity, but not VZV antibody, plays a critical role in limiting reactivation and replication of latent VZV and, thus, in preventing herpes zoster and its complications. Consequently, induction of VZV-specific cell-mediated immunity and not antibody should be used as a proxy for the clinical efficacy of new formulations and uses of zoster vaccine. Prospects for improved zoster vaccines and their use in immunocompromised patients are discussed, and questions related to zoster vaccine use are addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citationLevin, M. J., Smith, J. G., Kaufhold, R. M., Barber, D., Hayward, A. R., Chan, C. Y., Chan, I. S. F., Li, D. J. J., Wang, W., Keller, P. M., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/379048 · Cited by 314
Cited by
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Varicella zoster virus infection
Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., Grose, C., Hambleton, S., Kennedy, P. G. E., Oxman, M. N., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.16 · Cited by 910
Self-citationOral complications of cancer and cancer therapy: From cancer treatment to survivorship
Epstein, J. B., Thariat, J., Bensadoun, R., Barasch, A., Murphy, B. A., Kolnick, L., Popplewell, L., & Maghami, E. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21157 · Cited by 518
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Schmader, K. E., Levin, M. J., Gnann, J. W., McNeil, S. A., Vesikari, T., Betts, R. F., Keay, S., Stek, J. E., Bundick, N. D., Su, S.-C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir970 · Cited by 430
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis497 · Cited by 147
The gracefully aging immune system
Boraschi, D., Aguado, M. T., Dutel, C., Goronzy, J., Louis, J., Grubeck-Loebenstein, B., Rappuoli, R., & Del Giudice, G. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005624 · Cited by 113
Irwin, M. R., Levin, M. J., Laudenslager, M. L., Olmstead, R., Lucko, A., Lang, N., Carrillo, C., Stanley, H. A., Caulfield, M. J., Weinberg, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis1208 · Cited by 81
Self-citationOhfuji, S., Ito, K., Inoue, M., Ishibashi, M., Kumashiro, H., Hirota, Y., Kayano, E., & Ota, N. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3719-7 · Cited by 18
Metadata
- Authors
- Oxman, M. N.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-07-15
- Volume
- 51
- Issue
- 2
- Pages
- 197-213
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1992354372
- Cited by
- 133
- References
- 2
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.